HER2-Positive Breast Cancer | Clinical

CNS-PFS Prolonged With Tucatinib Plus Palbociclib/Letrozole in HR+/HER2+ Breast Cancer

December 08, 2021

A non-chemotherapy–based targeted regimen comprised of tucatinib, palbociclib, and letrozole was found to prolong central nervous system (CNS) progression-free survival (PFS) in patients with hormone receptor–positive, HER2-positive breast cancer.

Further Exploration of the HER2CLIMB Regimen in Pretreated HER2 Breast Cancer

October 27, 2021

Guiseppe Curigliano, MD, discusses the rationale behind a subgroup HER2CLIMB study, which evaluated the efficacy and safety of tucatinib in combination with trastuzumab and capecitabine in pretreated HER2-positive breast cancer patients with and without brain metastases compared with placebo.

Novel Device May Predict Response to Therapy in Patients With Early Breast Cancer

October 27, 2021

Frederick Howard, MD, a medical oncology fellow in the Department of Medicine at the University of Chicago, discussed the clinical benefits of the SimBioSys TumorScope model for the treatment of early breast cancer in an interview with Targeted Oncology.

Data Supporting Trastuzumab/Pertuzumab Use In HER2+ Breast Cancer with Leptomeningeal Disease

October 07, 2021

Kamran A. Ahmed, MD, discusses the data leading up to the phase 1/2 study of radiotherapy followed by intrathecal trastuzumab and pertuzumab for the management of HER2-positive breast cancer with leptomeningeal disease and what impact the study may have on the community oncology space.

Differences Between the Global and Asian HER2+ BC Cohorts in the KAMILLA Trial

October 02, 2021

Rachel Wuerstein, MD, of the Unïversität Müchen, discusses the differences between the global and Asian cohorts in the KAMILLA trial (NCT01702571), which evaluates the benefit of trastuzumab emtansine (T-DM1, Kadcyla) in patients with HER2-positive breast cancer who have received prior anti-HER2 and chemotherapy-based treatment.

Following De-Escalated Neoadjuvant T-DM1 in HR+/HER2+ Early Breast Cancer, Biomarkers May Predict Outcomes

September 20, 2021

When comparing de-escalated neoadjuvant ado-trastuzumab emtansine, with or without endocrine therapy, vs trastuzumab plus endocrine therapy baseline tumor immunogenicity may be associated with higher pathologic complete response rates and favorable outcomes in hormone receptor-positive, human epidermal growth factor receptor 2-positive early stage breast cancer.